Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GlaxoSmithKline plc announces changes to its Board and Committees
GlaxoSmithKline plc today announces the following changes to its Board and Committee structure.
GSK and Theravance announce FDA acceptance of FF/VI New Drug Application (NDA) submission in the US for COPD
GSK & THRX announced New Drug Application for vilanterol for patients with COPD, has been accepted by the FDA meaning it's ready for review.
Regulatory Update: GSK announces submission for a new indication for Synflorix™ in Europe
GSK submitted a regulatory application in EU seeking approval of Synflorix, a Streptococcus pneumococcal vaccine for infants and children.
GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash
GSK announces that it has acquired 5Mil newly issued shares of Response Genetics Inc. common stock at a price of US$1.10 per share in cash.
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD
GSK & THRX announced completion of phase III programme of LAMA/LABA involving approx. 6,000 patients with COPD.
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis
GSK & Janssen announced, Phase III programme evaluating sirukumab, (IL)-6 monoclonal antibody in the treatment of RA, has commenced dosing.
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
GSK announced it's reached agreement to divest majority of its Classic Brands in Australia to Aspen for approximately £172 million in cash.
European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
GSK announced today the EC has granted pazopanib marketing authorisation for the treatment of aSTS who have received prior chemotherapy.
GSK completes acquisition of Human Genome Sciences
GSK announced it has completed acquisition of HGS for US$3.6 billion equity. outstanding shares acquired for US$14.25 per share in cash.
Regulatory update – GSK announces submissions in the EU and US for dabrafenib and trametinib
GSK announced submissions in EU & US related to single-agent use of dabrafenib & trametinib to treat BRAF V600 mutation metastatic melanoma.
GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period
GlaxoSmithKline plc (LSE: GSK) today announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences.
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
Results announcement for the second quarter 2012
GSK delivers Q2 core EPS of 26.4p and dividend of 17p
GSK pre-broadcast statement on BBC Panorama: “The truth about Sports Products”, 19 July 2012
GSK issued statement in anticipation of BBC Panorama programme. The truth about sports products, scheduled to be aired this evening.
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
GSK & FOLD announced an expansion of their collaboration to develop the investigational pharmacological migalastat HCl for Fabry disease.
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GSK & HGS announced they have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK, Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games celebrating with anti-doping science campaign.
US Regulatory Update – Tykerb® (lapatinib)
GSK announced it has withdrawn a sNDA to the FDA for lapatinib with trastuzumab for HER2 (ErbB2)-positive metastatic breast cancer
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes
GSK announced data have been received from Phase III Harmony 8 study of cardiovascular safety conducted across the albiglutide programme.
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi-ViiV announced results received from Phase III SINGLE study of dolutegravir in treatment-naive adults with HIV-1.